Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants

RICHMOND HILL, ONTARIO – Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that it has appointed Marcum LLP as the Company’s new auditor, replacing BDO Canada LLP. The Company has filed a Notice of Change of Auditor in respect of this change under its SEDAR profile at www.sedar.com.